The Psychedelic News Feed: April 1, 2024 – Psychedelic Alpha

PSYCHEDELIC DRUG DEVELOPMENT NEWS

Drug Developer Skips the Trip Entirely, Unveils Deuterium-Assisted Psychotherapy Candidate (Apr 1)

Initial reports describe the experience, though lacking psychedelics’ characteristic subjective effects, as “heavy” and “somewhat unstable”, but “noticeably patentable”.

Company Receives Notice of Allowance for U.S. Patent Covering Crystalline Polymorphs of Water (Apr 1)

The company announced the claims cover its lead candidate, Polymorph Eau.

The love my daughter and I found in the PICU

The ventilator alarm woke me at 3 a.m. It was the fourth alarm in the past two hours. My 5-year-old daughter Molly had been there

June 29, 2023

Pharma companies question new EU incentives as revamp advances

Members of a committee for the European Parliament on Tuesday signed off on a new legislative overhaul that aims to make their continent more attractive

March 20, 2024

Gilead licenses HIV shot to six generic manufacturers, but falls short of access sought by advocates

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.